HC Wainwright Comments on Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Kura Oncology in a research note issued to investors on Thursday, February 27th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.80) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology's Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

Several other equities analysts also recently commented on KURA. JMP Securities reiterated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, November 21st. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology currently has an average rating of "Moderate Buy" and a consensus target price of $27.13.

Remove Ads

Kura Oncology Trading Up 1.1 %

NASDAQ:KURA traded up $0.08 during midday trading on Friday, hitting $7.33. 1,574,644 shares of the company traded hands, compared to its average volume of 1,599,634. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm's fifty day moving average is $8.10 and its 200-day moving average is $13.64. The firm has a market capitalization of $570.01 million, a P/E ratio of -3.11 and a beta of 0.85. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last 90 days. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. purchased a new stake in shares of Kura Oncology during the fourth quarter worth about $38,769,000. Millennium Management LLC grew its position in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after purchasing an additional 1,521,954 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Kura Oncology during the 4th quarter valued at approximately $8,518,000. Marshall Wace LLP acquired a new stake in shares of Kura Oncology during the fourth quarter worth $8,265,000. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Kura Oncology by 172.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock valued at $10,027,000 after acquiring an additional 727,987 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.